Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia : The PRISONAFLD Study
Rivera Esteban, Jesús (Universitat Autònoma de Barcelona. Departament de Medicina)
Jiménez-Masip, Alba (Universitat Autònoma de Barcelona. Departament de Medicina)
Muñoz-Martínez, S. (Hospital Universitari Vall d'Hebron)
Augustin Recio, Salvador (Vall d'Hebron Institut de Recerca (VHIR))
Guerrero, Rafael A. (Institut Català de la Salut)
Gabriel-Medina, Pablo (Hospital Universitari Vall d'Hebron)
Ferrer Costa, Roser (Hospital Universitari Vall d'Hebron)
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron)
Turu, Elisabet (Institut Català de la Salut)
Marco, Andrés (Institut Català de la Salut)
Pericàs, Juan M. (Hospital Universitari Vall d'Hebron)

Data:	2023
Resum:	Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29. 7%) had metabolic disorders, and 646 (14. 9%) underwent VCTE. The mean age was 48. 0 years (SD 12. 1), and 89. 5% were male. MASLD prevalence was 33. 9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16. 4% and 9. 4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Non-alcoholic fatty liver disease ; Metabolic dysfunction-associated steatotic liver disease ; Metabolic syndrome ; Liver fibrosis ; Prison
Publicat a:	Journal of clinical medicine, Vol. 12 (november 2023) , ISSN 2077-0383

DOI: 10.3390/jcm12237276
PMID: 38068330

12 p, 910.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats